Comparing Innovation Spending: Dr. Reddy's Laboratories Limited and Amneal Pharmaceuticals, Inc.

R&D Spending: Dr. Reddy's vs. Amneal Pharmaceuticals

__timestampAmneal Pharmaceuticals, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 201410673500012402000000
Thursday, January 1, 201513687000017449000000
Friday, January 1, 201620474700017834000000
Sunday, January 1, 201719193800019551000000
Monday, January 1, 201821045100018265000000
Tuesday, January 1, 201920228700015607000000
Wednesday, January 1, 202019058500015410000000
Friday, January 1, 202120956300016541000000
Saturday, January 1, 202220004600017482000000
Sunday, January 1, 202316777800019381000000
Monday, January 1, 202422873000000
Loading chart...

Data in motion

Innovation Spending: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, innovation is key. Dr. Reddy's Laboratories Limited and Amneal Pharmaceuticals, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, Dr. Reddy's consistently outspent Amneal, with R&D expenses peaking at approximately $19.4 billion in 2023, a staggering 1,700% more than Amneal's $168 million. This trend highlights Dr. Reddy's commitment to innovation, even as Amneal's spending fluctuated, reaching its highest in 2018. Notably, Dr. Reddy's R&D investment grew by 56% from 2014 to 2023, underscoring its strategic focus on long-term growth. As we look to the future, the absence of data for Amneal in 2024 raises questions about its ongoing innovation strategy. This comparison offers a fascinating glimpse into how these companies prioritize and allocate resources for innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025